Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review
Open Access
- 4 May 2010
- journal article
- review article
- Published by Wiley in International Journal of Cancer
- Vol. 128 (5), 1080-1094
- https://doi.org/10.1002/ijc.25432
Abstract
A cyclin‐dependent kinase inhibitor CDKN2A (p16/Ink4a) is a tumor suppressor and upregulated in cellular senescence. CDKN2A promoter methylation and gene silencing are associated with the CpG island methylator phenotype (CIMP) in colon cancer. However, prognostic significance of CDKN2A methylation or loss of CDKN2A (p16) expression independent of CIMP status remains uncertain. Using a database of 902 colorectal cancers in 2 independent cohort studies (the Nurses' Health Study and the Health Professionals Follow‐up Study), we quantified CDKN2A promoter methylation and detected hypermethylation in 269 tumors (30%). By immunohistochemistry, we detected loss of CDKN2A (p16) expression in 25% (200/804) of tumors. We analyzed for LINE‐1 hypomethylation and hypermethylation at 7 CIMP‐specific CpG islands (CACNA1G, CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1); microsatellite instability (MSI); KRAS, BRAF and PIK3CA mutations; and expression of TP53 (p53), CTNNB1 (β‐catenin), CDKN1A (p21), CDKN1B (p27), CCND1 (cyclin D1), FASN (fatty acid synthase) and PTGS2 (cyclooxygenase‐2). CDKN2A promoter methylation and loss of CDKN2A (p16) were associated with shorter overall survival in univariate Cox regression analysis [hazard ratio (HR): 1.36, 95% CI: 1.10–1.66, p = 0.0036 for CDKN2A methylation; HR: 1.30, 95% CI: 1.03–1.63, p = 0.026 for CDKN2A (p16) loss] but not in multivariate analysis that adjusted for clinical and tumor variables, including CIMP, MSI and LINE‐1 methylation. Neither CDKN2A promoter methylation nor loss of CDKN2A (p16) was associated with colorectal cancer‐specific mortality in uni‐ or multivariate analysis. Despite its well‐established role in carcinogenesis, CDKN2A (p16) promoter methylation or loss of expression in colorectal cancer is not independently associated with patient prognosis.Keywords
Funding Information
- U.S. National Institute of Health (P01 CA87969, P01 CA55075, P50 CA127003, K07 CA122826)
- The Bennett Family Fund
- Entertainment Industry Foundation through National Colorectal Cancer Research Alliance
- japan society for promotion of science
This publication has 62 references indexed in Scilit:
- Tumor suppressor mechanisms in immune agingCurrent Opinion in Immunology, 2009
- A Cohort Study of Tumoral LINE-1 Hypomethylation and Prognosis in Colon CancerJNCI Journal of the National Cancer Institute, 2008
- Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotypeHistopathology, 2008
- CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancerGut, 2008
- Epigenetic-Genetic Interactions in theAPC/WNT, RAS/RAF, andP53Pathways in Colorectal CarcinomaClinical Cancer Research, 2008
- The aberrant methylation of TSP1 suppresses TGF‐β1 activation in colorectal cancerInternational Journal of Cancer, 2008
- LINE‐1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancerInternational Journal of Cancer, 2008
- Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2The New England Journal of Medicine, 2007
- Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotypeHuman Pathology, 2007
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006